Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

At Monte Rosa Therapeutics, we are passionate about developing new therapies to improve the lives of patients with severe and life-threatening diseases. We believe in the power of science and are committed to advancing our understanding of the immune system and applying our insights to help people.

Our vision is to build a world-leading biopharmaceutical company focused on developing breakthrough therapeutics that address serious unmet medical needs in immuno-modulation. We strive to develop therapies that significantly reduce symptoms and improve patient outcomes. We believe in collaboration and partnering with those that share our commitment to the advancement of human health.

Monte Rosa Therapeutics has won numerous awards, including the 2015 Drug Manufacturer & Discovery Award for its LPAR1-Targeted Immunomodulator program and the 2016 Tribune Innovation Award for its innovative drug discovery platform.